View conference programme - The British Society for Rheumatology

SJÖGREN’S SYNDROME (236 – 239)
236 HEALTH CARE USAGE IN PRIMARY SJÖGREN’S SYNDROME.
R Callaghan 1 , A Prabu 1 , C Gordon 1 , A Clarke 2 , S Bowman 1 . 1
Rheumatology Department, Division of
Immunity & Infection, The University of Birmingham, Birmingham, United Kingdom; 2 Department of
Medicine, McGill University, Montreal, QC, Canada
237 A STUDY INTO THE INCIDENCE OF AUTOIMMUNE DISEASES IN A COHORT OF PATIENTS
WITH PRIMARY SJOGREN’S SYNDROME.
MN Lazarus, DA Isenberg. Centre for Rheumatology, University College London, London,
United Kingdom
238 SYMPTOMS OF OCULAR AND ORAL DRYNESS IN AN UNSELECTED POPULATION OF PATIENTS
ATTENDING A RHEUMATOLOGY CLINIC.
G Hamad, E Price. Department of Rheumatology, Great Western Hospital, Swindon, Wiltshire,
United Kingdom
239 HLA GENOTYPES IN PRIMARY SJÖGREN’S SYNDROME COMPARED TO A NORTH EAST OF
ENGLAND CONTROL GROUP.
C Morley 1 , V Carter 2 , G Cavanagh 2 , NJ Marshall 1 , ID Griffiths 1 . 1
Rheumatology Department, Freeman
Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 2 Histocompatibility and
Immunogenetics Department, National Blood Service, Newcastle upon Tyne, Tyne and Wear,
United Kingdom
SLE AND ANTIPHOSPHOLIPID SYNDROME (240 – 264)
240 SPONTANEOUS AUTOIMMUNITY AND ITS EPISTATIC MODIFICATION IN 129 AND C57BL/6 MICE
- IMPLICATIONS FOR AUTOIMMUNITY DESCRIBED IN GENE-TARGETED MICE.
J Cortes-Hernandez, AE Bygrave, KL Rose, J Warren, TH Cook, MJ Walport, T Vyse, M Botto.
Rheumatology Section, Eric Bywaters Centre, Imperial College, London, London, United Kingdom
241 TNF HAPLOTYPES WITH SEROLOGICAL SUBSETS OF SLE.
NJ McHugh 1 , PA Owen 2 , B Cox 2 , J Dunphy 2 , KI Welsh 3 . 1
Rheumatology, Royal National Hospital for
Rheumatic Diseases, Bath, Banes, United Kingdom; 2 BIRD Diagnostics, Bath Institute for Rheumatic
Diseases, Bath, Banes, United Kingdom; 3 Clinical Genomics, National Heart and Lung Institute, London,
United Kingdom
242 A COMBINATION OF LOSS OF SLE SUSCEPTIBILITY INTERVALS AND ACQUISITION OF
SUPPRESSOR LOCI RESULTS IN DISEASE RESISTANCE IN BXSB/LONG-LIVED MICE.
MEK Haywood 1 , J Rose 1 , S Izui 2 , BJ Morley 1 . 1
Rheumatology Section, Eric Bywaters Centre, Imperial
College, London, United Kingdom; 2 Department of Pathology, Centre Medical Universitaire, Geneva,
United Kingdom
243 RE-THROMBOSIS AND BLEEDING IN PRIMARY ANTIPHOSPHOLIPID SYNDROME PATIENTS ON
ORAL ANTICOAGULATION AT A TARGET INR 2.0-3.0. A LONGITUDINAL COMPARISON WITH
PATIENTS WITH INHERITED THROMBOPHILIA AND AORTIC VALVE REPLACEMENTS.
PRJ Ames 1 , A Ciampa 2 , M Maurizio 3 , S Giovanna 3 , B Vincenzo 3 , I Luigi 3 . 1
Academic Department of
Rheumatology, Leeds General Infirmary, Leeds, United Kingdom; 2 Unita’ Semplice di Emostasi e
Trombosi, Ospedale A. Moscati, Avellino, Italy; 3 Unita’ Semplice di Emostasi e Trombosi, Ospedale A
Cardarelli, Naples, Italy
244 COELIAC ARTERY STENOSIS AND ANTIPHOSPHOLIPID ANTIBODIES.
G Obermoser, IS Lau, S Sangle, D D’Cruz, GRV Hughes. Lupus Research Unit, The Rayne Institute,
St Thomas’ Hospital, London, United Kingdom
60